<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Galantamine is an <z:chebi fb="0" ids="38462">acetylcholinesterase inhibitor</z:chebi> and memantine is a non competitive <z:chebi fb="68" ids="48706">antagonist</z:chebi> of <z:chebi fb="0" ids="31882">NMDA</z:chebi> receptors that are being used to treat <z:e sem="disease" ids="C0002395" disease_type="Disease or Syndrome" abbrv="SDAT">Alzheimer's disease</z:e> (AD) patients </plain></SENT>
<SENT sid="1" pm="."><plain>The fact that drugs with different mechanisms of action are available to treat AD introduces the prospect of prescribing drug combinations to amplify drug efficacy </plain></SENT>
<SENT sid="2" pm="."><plain>This study was planed to evaluate the potential neuroprotective effects of galantamine combined with memantine in a transient global <z:hpo ids='HP_0002637'>cerebral ischemia</z:hpo> model in gerbils </plain></SENT>
<SENT sid="3" pm="."><plain>Animal groups included in the study were: sham, <z:e sem="disease" ids="C0022116" disease_type="Disease or Syndrome" abbrv="">ischemia</z:e>, and <z:e sem="disease" ids="C0022116" disease_type="Disease or Syndrome" abbrv="">ischemia</z:e> plus galantamine (1 mg/kg and 10 mg/kg), memantine (10 mg/kg and 20 mg/kg), 1 mg/kg galantamine plus 10 mg/kg memantine, and 10 mg/kg galantamine plus 10 mg/kg memantine, respectively </plain></SENT>
<SENT sid="4" pm="."><plain>Surviving pyramidal neurons in the CA1 subfield of the hippocampus, TUNEL, caspase-3 and SOD-2 immunohistochemistries, and the object placement test were evaluated 72 h after reperfusion </plain></SENT>
<SENT sid="5" pm="."><plain>Memantine did not exert a clear neuroprotective effect, nor did it prevent spatial <z:hpo ids='HP_0002354'>memory loss</z:hpo> </plain></SENT>
<SENT sid="6" pm="."><plain>In a previous study using the same experimental model, galantamine was neuroprotective and improved spatial memory </plain></SENT>
<SENT sid="7" pm="."><plain>In this study, the association of 10 mg/kg memantine with 10 mg/kg galantamine increased the number of living pyramidal neurons, reduced TUNEL, active caspase-3 and SOD-2 immunoreactivity, and preserved spatial memory after <z:e sem="disease" ids="C0022116" disease_type="Disease or Syndrome" abbrv="">ischemia</z:e>-reperfusion injury; however, the effects of the combination were not statistically different from those observed in animals treated with galantamine alone </plain></SENT>
<SENT sid="8" pm="."><plain>We believe these results are of interest from a clinical point of view because the association of both drugs is being used in clinical practice and in clinical trials to treat <z:e sem="disease" ids="C0002395" disease_type="Disease or Syndrome" abbrv="SDAT">Alzheimer's disease</z:e> and vascular <z:hpo ids='HP_0000726'>dementia</z:hpo> </plain></SENT>
</text></document>